<p>argenx SE（NASDAQ:ARGX - 获取免费报告）的股票在覆盖该股票的 24 家研究公司中获得了平均 “买入” 的推荐，MarketBeat Ratings 报告称。两位研究分析师对该股票给予了持有的推荐，20 位分析师给予了买入的推荐，另外两位分析师对该公司给予了强烈买入的推荐。在过去一年中，覆盖该股票的经纪人给出的平均一年目标价格为 817.5263 美元。</p>
<ul>
<li>3 家医疗行业的开创者，拥有长期的顺风</li>
</ul>
<p>几位分析师最近对 ARGX 股票发表了看法。Wedbush 在 10 月 13 日的研究报告中将 argenx 的目标价格从 800.00 美元上调至 880.00 美元，并给予该公司 “跑赢大盘” 的评级。Stifel Nicolaus 在 9 月 18 日的研究报告中为 argenx 设定了 882.00 美元的目标价格。摩根士丹利在 10 月 1 日的研究报告中将 argenx 的目标价格从 766.00 美元上调至 1,040.00 美元，并给予该公司 “增持” 的评级。Zacks Research 在 9 月 22 日的研究报告中将 argenx 的评级从 “持有” 上调至 “强烈买入”。最后，富国银行在 7 月 31 日的研究报告中将 argenx 的目标价格从 741.00 美元上调至 756.00 美元，并给予该公司 “增持” 的评级。</p>
<p><strong>查看我们关于 argenx 的最新报告</strong></p>
<h2>对 argenx 的对冲基金看法</h2>
<ul>
<li>5 只盈利增长三位数的医疗股票</li>
</ul>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。WPG Advisers LLC 在第一季度以约 37,000 美元的估值收购了 argenx 的新头寸。Golden State Wealth Management LLC 在第一季度以约 44,000 美元的估值收购了 argenx 的新头寸。Brooklyn Investment Group 在第一季度将其在 argenx 的持股增加了 102.7%。Brooklyn Investment Group 现在拥有 75 股该公司的股票，估值为 44,000 美元，此前在上个季度又购买了 38 股。MAI Capital Management 在第二季度将其在 argenx 的持股增加了 866.7%。MAI Capital Management 现在拥有 87 股该公司的股票，估值为 48,000 美元，此前在上个季度又购买了 78 股。最后，Banque Transatlantique SA 在第一季度收购了约 62,000 美元的 argenx 新头寸。目前，60.32% 的股票由机构投资者和对冲基金持有。</p>
<h2>argenx 股票表现</h2>
<p>argenx 股票在周五开盘价为 843.66 美元。该公司的 50 日简单移动平均线为 734.69 美元，200 日简单移动平均线为 635.98 美元。argenx 的 12 个月低点为 510.05 美元，12 个月高点为 849.99 美元。该公司的市值为 516.3 亿美元，市盈率为 43.26，市盈率增长比率为 0.91，贝塔值为 0.46。</p>
<ul>
<li>Argenx 的 28% 激增和有前景的产品提升了投资者信心</li>
</ul>
<p>argenx（NASDAQ:ARGX - 获取免费报告）在 7 月 31 日最后发布了其财报。该公司报告本季度每股收益为 3.74 美元，超出市场共识预期的 2.84 美元，超出 0.90 美元。argenx 的净利润率为 40.98%，股本回报率为 21.06%。该业务本季度的收入为 8.6679 亿美元，而分析师预期为 7.7682 亿美元。平均而言，股票分析师预测 argenx 在当前财政年度每股收益为 3.13 美元。</p>
<h2>argenx 公司简介</h2>
<p>(获取免费报告)</p>
<p>argenx SE 是一家生物技术公司，致力于开发各种治疗自身免疫性疾病的疗法，覆盖美国、日本、欧洲、中东、非洲和中国。其主要产品候选药物是 efgartigimod，用于治疗重症肌无力、免疫性血小板减少症、天疱疮、广泛性重症肌无力、慢性炎症性脱髓鞘性多发性神经病、甲状腺眼病、疱疹性皮肤病、肌炎、原发性干燥综合症、后新冠姿势性心动过速综合症、膜性肾病、狼疮性肾病、与 ANCA 相关的血管炎和抗体介导的排斥反应；ENHANZE SC；Empasiprubart 用于多灶性运动神经病、延迟移植物功能和皮肌炎；以及 ARGX-119 用于先天性重症肌无力综合症和肌萎缩侧索硬化症。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，而不是 argenx</li>
<li>上海证券交易所综合指数是什么？</li>
<li>强生的并购战略是投资者真正关注的故事</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>特斯拉：一些分析师预测将下跌 30%——是时候恐慌了吗？</li>
<li>股票中的死亡交叉是什么？</li>
<li>对冲基金对美元的态度转变——这是这三只股票的买入信号吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 argenx 吗？</h2>
<p>在考虑投资 argenx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 argenx 并不在名单上。</p>
<p>虽然 argenx 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ARGX

<p>阿根克斯公司（NASDAQ:ARGX）的股票获得了 24 家研究机构的平均 “买入” 推荐。分析师设定的 1 年目标价平均为 817.53 美元，最近 Wedbush 将目标价上调至 880.00 美元，摩根士丹利上调至 1,040.00 美元。机构投资者持有该股票的 60.32%。该公司报告每股收益为 3.74 美元，超出预期，收入为 8.6679 亿美元。阿根克斯专注于自身免疫疾病的治疗，其主要产品候选药物为 efgartigimod</p>

<p>Shares of argenex SE (NASDAQ:ARGX - Get Free Report) have earned an average recommendation of &#34;Buy&#34; from the twenty-four research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, twenty have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $817.5263.</p>
<div class="lb-trans"><p>argenx SE（NASDAQ:ARGX - 获取免费报告）的股票在覆盖该股票的 24 家研究公司中获得了平均 “买入” 的推荐，MarketBeat Ratings 报告称。两位研究分析师对该股票给予了持有的推荐，20 位分析师给予了买入的推荐，另外两位分析师对该公司给予了强烈买入的推荐。在过去一年中，覆盖该股票的经纪人给出的平均一年目标价格为 817.5263 美元。</p>
</div><ul>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家医疗行业的开创者，拥有长期的顺风</li>
</ul>
</div><p>Several analysts have recently weighed in on ARGX shares. Wedbush lifted their target price on shares of argenex from $800.00 to $880.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, October 13th. Stifel Nicolaus set a $882.00 target price on shares of argenex in a research report on Thursday, September 18th. Morgan Stanley boosted their price target on shares of argenex from $766.00 to $1,040.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, October 1st. Zacks Research upgraded shares of argenex from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, September 22nd. Finally, Wells Fargo &amp; Company boosted their price target on shares of argenex from $741.00 to $756.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, July 31st.</p>
<div class="lb-trans"><p>几位分析师最近对 ARGX 股票发表了看法。Wedbush 在 10 月 13 日的研究报告中将 argenx 的目标价格从 800.00 美元上调至 880.00 美元，并给予该公司 “跑赢大盘” 的评级。Stifel Nicolaus 在 9 月 18 日的研究报告中为 argenx 设定了 882.00 美元的目标价格。摩根士丹利在 10 月 1 日的研究报告中将 argenx 的目标价格从 766.00 美元上调至 1,040.00 美元，并给予该公司 “增持” 的评级。Zacks Research 在 9 月 22 日的研究报告中将 argenx 的评级从 “持有” 上调至 “强烈买入”。最后，富国银行在 7 月 31 日的研究报告中将 argenx 的目标价格从 741.00 美元上调至 756.00 美元，并给予该公司 “增持” 的评级。</p>
</div><p><strong>Check Out Our Latest Report on argenex</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 argenx 的最新报告</strong></p>
</div><h2>Hedge Funds Weigh In On argenex</h2>
<div class="lb-trans"><h2>对 argenx 的对冲基金看法</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只盈利增长三位数的医疗股票</li>
</ul>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. WPG Advisers LLC acquired a new position in argenex in the first quarter valued at about $37,000. Golden State Wealth Management LLC acquired a new position in argenex in the first quarter valued at about $44,000. Brooklyn Investment Group boosted its position in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company's stock valued at $44,000 after buying an additional 38 shares in the last quarter. MAI Capital Management boosted its position in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company's stock valued at $48,000 after buying an additional 78 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new position in shares of argenex during the first quarter worth approximately $62,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。WPG Advisers LLC 在第一季度以约 37,000 美元的估值收购了 argenx 的新头寸。Golden State Wealth Management LLC 在第一季度以约 44,000 美元的估值收购了 argenx 的新头寸。Brooklyn Investment Group 在第一季度将其在 argenx 的持股增加了 102.7%。Brooklyn Investment Group 现在拥有 75 股该公司的股票，估值为 44,000 美元，此前在上个季度又购买了 38 股。MAI Capital Management 在第二季度将其在 argenx 的持股增加了 866.7%。MAI Capital Management 现在拥有 87 股该公司的股票，估值为 48,000 美元，此前在上个季度又购买了 78 股。最后，Banque Transatlantique SA 在第一季度收购了约 62,000 美元的 argenx 新头寸。目前，60.32% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>argenex Stock Performance</h2>
<div class="lb-trans"><h2>argenx 股票表现</h2>
</div><p>Shares of argenex stock opened at $843.66 on Friday. The firm's 50-day simple moving average is $734.69 and its 200-day simple moving average is $635.98. argenex has a twelve month low of $510.05 and a twelve month high of $849.99. The firm has a market cap of $51.63 billion, a P/E ratio of 43.26, a price-to-earnings-growth ratio of 0.91 and a beta of 0.46.</p>
<div class="lb-trans"><p>argenx 股票在周五开盘价为 843.66 美元。该公司的 50 日简单移动平均线为 734.69 美元，200 日简单移动平均线为 635.98 美元。argenx 的 12 个月低点为 510.05 美元，12 个月高点为 849.99 美元。该公司的市值为 516.3 亿美元，市盈率为 43.26，市盈率增长比率为 0.91，贝塔值为 0.46。</p>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增和有前景的产品提升了投资者信心</li>
</ul>
</div><p>argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The business had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. On average, equities analysts forecast that argenex will post 3.13 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>argenx（NASDAQ:ARGX - 获取免费报告）在 7 月 31 日最后发布了其财报。该公司报告本季度每股收益为 3.74 美元，超出市场共识预期的 2.84 美元，超出 0.90 美元。argenx 的净利润率为 40.98%，股本回报率为 21.06%。该业务本季度的收入为 8.6679 亿美元，而分析师预期为 7.7682 亿美元。平均而言，股票分析师预测 argenx 在当前财政年度每股收益为 3.13 美元。</p>
</div><h2>argenex Company Profile</h2>
<div class="lb-trans"><h2>argenx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.</p>
<div class="lb-trans"><p>argenx SE 是一家生物技术公司，致力于开发各种治疗自身免疫性疾病的疗法，覆盖美国、日本、欧洲、中东、非洲和中国。其主要产品候选药物是 efgartigimod，用于治疗重症肌无力、免疫性血小板减少症、天疱疮、广泛性重症肌无力、慢性炎症性脱髓鞘性多发性神经病、甲状腺眼病、疱疹性皮肤病、肌炎、原发性干燥综合症、后新冠姿势性心动过速综合症、膜性肾病、狼疮性肾病、与 ANCA 相关的血管炎和抗体介导的排斥反应；ENHANZE SC；Empasiprubart 用于多灶性运动神经病、延迟移植物功能和皮肌炎；以及 ARGX-119 用于先天性重症肌无力综合症和肌萎缩侧索硬化症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than argenex</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>What is a Death Cross in Stocks?</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 argenx</li>
<li>上海证券交易所综合指数是什么？</li>
<li>强生的并购战略是投资者真正关注的故事</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>特斯拉：一些分析师预测将下跌 30%——是时候恐慌了吗？</li>
<li>股票中的死亡交叉是什么？</li>
<li>对冲基金对美元的态度转变——这是这三只股票的买入信号吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ARGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in argenex Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 argenx 吗？</h2>
</div><p>Before you consider argenex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 argenx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 argenx 并不在名单上。</p>
</div><p>While argenex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 argenx 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

argenex SE（NASDAQ 代码：ARGX）被券商给予 “买入” 平均评级